CONMED CorporationCNMD stock score: 57/100
$46.38 · -3.40% · Scored Nov 19, 2026
- Technical
- 40
- Fundamental
- 61
- News
- 44
The reading
CONMED (CNMD) scores 57 out of 100, which reads neutral, higher than 68% of Healthcare stocks and 67% of the 4,118 US stocks we score.
The composite weights fundamentals 80% and technicals 20%: fundamentals read 61, technicals 40.
Among the fundamentals, Free Cash Flow Yield at 98 and Forward P/E at 96 score highest, while Earnings Growth (Annual) at 0 weighs the most against it.
On the daily chart, trend-following indicators average 39 and contrarian oscillators 55.
News sentiment is neutral at 44; it is shown, not counted in the composite.
Since Aug 22, 2026 the composite has ranged from 44 to 60, and it is up 7 points over the period.
About CONMED
CONMED (CNMD) is a medical device company that makes instruments and implants used in minimally invasive surgery, sports medicine and general surgery. Its orthopedic business sells arthroscopy equipment, implants and soft tissue repair products such as the BioBrace scaffold, along with powered surgical tools, foot and ankle products and imaging systems. Its general surgery business includes the AirSeal system, which maintains steady pressure in the abdomen during laparoscopic and robotic procedures, Buffalo Filter devices that remove surgical smoke, and electrosurgery and other surgical instruments. CONMED has exited its gastroenterology product lines to focus on these core areas. Customers are hospitals, ambulatory surgery centers and surgeons, reached through a direct sales force in many countries and through distributors elsewhere. The company earns most of its revenue from single-use disposable products, so procedure volumes drive repeat sales.
CONMED competes with Arthrex, Smith & Nephew, Stryker, Johnson & Johnson MedTech, Medtronic and Olympus. Its edge rests on products such as AirSeal and BioBrace that have few direct substitutes, compatibility with robotic surgery platforms and an installed base of capital equipment that pulls through disposables. Investors who follow CNMD stock tend to watch organic sales growth in orthopedics and general surgery. AirSeal supply and adoption are closely followed. Gross margins, tariffs, debt levels and procedure volumes in ambulatory surgery centers are other factors.
What’s driving the score
The strongest and weakest of the scorers that count toward CNMD’s composite. Each returns 0–100, higher is more bullish — including metrics where low is good, like P/E.
Fundamental
61Pulling it up
Free cash flow yield is free cash flow divided by market value: the cash a business generates for each dollar of its price.
Forward P/E ratio uses estimated future earnings to calculate valuation.
Price-to-Book ratio compares market value to book value.
Holding it back
Net income growth from the prior fiscal year to the latest.
Return on Equity (ROE) measures how efficiently a company generates profits from shareholder equity.
Gross margins show profitability after cost of goods sold.
38 weighted scorers; 1 had no data today and are left out rather than counted as zero.
Technical · daily
43Pulling it up
- SMA 20081
Simple Moving Average (200-period) is the most widely followed long-term trend indicator.
Williams %R (7-period) places the close within the last 7 periods' high-low range.
Know Sure Thing (KST) combines multiple rate-of-change calculations to identify long-term trend reversals.
Holding it back
Candlestick patterns recognize specific price formations that historically suggest continuation or reversal.
- VWAP2
Volume Weighted Average Price (VWAP) shows the average price weighted by volume.
Where the close sits against its 20-day SMA.
62 weighted scorers; 3 had no data today and are left out rather than counted as zero.
News · shown, not counted
- Global News
- 44
Technical score by timeframe
| Chart | Score | Weight |
|---|---|---|
| Hourly | 33 | 1 |
| Daily | 43 | 3 |
| Weekly | 44 | 2 |
| Monthly | 36 | 2 |
| Quarterly | 36 | 2 |
Composite score, last 90 days
Show the daily numbers
| Date | Composite |
|---|---|
| Nov 19, 2026 | 57 |
| Nov 18, 2026 | 58 |
| Nov 17, 2026 | 58 |
| Nov 16, 2026 | 59 |
| Nov 15, 2026 | 59 |
| Nov 14, 2026 | 59 |
| Nov 13, 2026 | 59 |
| Nov 12, 2026 | 60 |
| Nov 11, 2026 | 51 |
| Nov 10, 2026 | 51 |
| Nov 8, 2026 | 51 |
| Nov 7, 2026 | 51 |
| Nov 6, 2026 | 51 |
| Nov 5, 2026 | 51 |
| Nov 4, 2026 | 52 |
| Nov 3, 2026 | 49 |
| Nov 2, 2026 | 47 |
| Nov 1, 2026 | 45 |
| Oct 30, 2026 | 44 |
| Oct 29, 2026 | 45 |
| Oct 28, 2026 | 46 |
| Oct 27, 2026 | 47 |
| Oct 26, 2026 | 49 |
| Oct 25, 2026 | 50 |
| Oct 24, 2026 | 50 |
| Oct 23, 2026 | 50 |
| Oct 22, 2026 | 50 |
| Oct 21, 2026 | 49 |
| Oct 20, 2026 | 49 |
| Oct 19, 2026 | 48 |
| Oct 18, 2026 | 49 |
| Oct 17, 2026 | 49 |
| Oct 16, 2026 | 49 |
| Oct 15, 2026 | 49 |
| Oct 14, 2026 | 47 |
| Oct 13, 2026 | 47 |
| Oct 12, 2026 | 47 |
| Oct 11, 2026 | 46 |
| Oct 10, 2026 | 46 |
| Oct 9, 2026 | 46 |
| Oct 8, 2026 | 46 |
| Oct 7, 2026 | 45 |
| Oct 6, 2026 | 47 |
| Oct 5, 2026 | 49 |
| Oct 4, 2026 | 49 |
| Oct 3, 2026 | 49 |
| Oct 2, 2026 | 48 |
| Oct 1, 2026 | 47 |
| Sep 30, 2026 | 48 |
| Sep 29, 2026 | 48 |
| Sep 28, 2026 | 47 |
| Sep 27, 2026 | 47 |
| Sep 26, 2026 | 47 |
| Sep 25, 2026 | 47 |
| Sep 24, 2026 | 48 |
| Sep 23, 2026 | 49 |
| Sep 22, 2026 | 48 |
| Sep 21, 2026 | 46 |
| Sep 20, 2026 | 46 |
| Sep 19, 2026 | 46 |
| Sep 18, 2026 | 46 |
| Sep 17, 2026 | 47 |
| Sep 16, 2026 | 48 |
| Sep 15, 2026 | 48 |
| Sep 14, 2026 | 48 |
| Sep 13, 2026 | 47 |
| Sep 12, 2026 | 47 |
| Sep 11, 2026 | 47 |
| Sep 10, 2026 | 47 |
| Sep 9, 2026 | 47 |
| Sep 8, 2026 | 48 |
| Sep 7, 2026 | 49 |
| Sep 6, 2026 | 49 |
| Sep 5, 2026 | 49 |
| Sep 4, 2026 | 48 |
| Sep 3, 2026 | 48 |
| Sep 2, 2026 | 49 |
| Sep 1, 2026 | 49 |
| Aug 31, 2026 | 48 |
| Aug 30, 2026 | 48 |
| Aug 29, 2026 | 48 |
| Aug 28, 2026 | 49 |
| Aug 27, 2026 | 50 |
| Aug 26, 2026 | 49 |
| Aug 25, 2026 | 49 |
| Aug 24, 2026 | 51 |
| Aug 23, 2026 | 50 |
| Aug 22, 2026 | 50 |
Key facts
- Market cap
- $1.4B
- Sector
- Healthcare
- Industry
- Medical Devices
- Beta
- 0.90
- Risk grade (1–10)
- 1
- Next earnings
- Jan 27, 2027
Medical Device peers
| Company | Market cap | Score |
|---|---|---|
| INSP Inspire Medical Systems | $1.6B | 60 |
| BFLY Butterfly Network | $1.6B | 47 |
| ENOV Enovis | $1.5B | 47 |
| PRCT PROCEPT BioRobotics | $1.5B | 51 |
| NVCR NovoCure | $1.2B | 44 |
| TNDM Tandem Diabetes Care | $1.2B | 38 |
Questions
What is CNMD's stock rating today?
CNMD scores 57/100 (Neutral) as of Nov 19, 2026: technical 40, fundamental 61, and news sentiment 44, which is shown but not counted. Scores are recomputed every night.
What does CONMED do?
CONMED (CNMD) is a medical device company that makes instruments and implants used in minimally invasive surgery, sports medicine and general surgery. Its orthopedic business sells arthroscopy equipment, implants and soft tissue repair products such as the BioBrace scaffold, along with powered surgical tools, foot and ankle products and imaging systems.
Is CNMD stock a buy?
The score is not a buy or sell recommendation. A 57 says the technical and fundamental signals we measure lean neutral today, relative to every other stock scored the same way. Use the breakdown above to see why, and treat it as a starting point for your own research.
How is the CNMD score calculated?
100 weighted scorers feed it today: 38 fundamental, scored against Healthcare ranges, and 62 technical on the daily chart, with 5 timeframes blended into the technical total. Every scorer returns 0–100; missing data is left out, never counted as zero.
Scores are information, not investment advice. Computed from Yahoo Finance, Finnhub and Alpha Vantage data; technical indicators via TA-Lib. Past scores do not predict future returns.
Embed this score
A badge for a blog post, newsletter or README. It updates every night and links back here. More badges
HTML
<a href="https://stocksscores.com/stocks/cnmd/"><img src="https://stocksscores.com/stocks/cnmd/badge.svg" alt="CNMD stock score" height="20"></a>
Markdown
[](https://stocksscores.com/stocks/cnmd/)